These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34051122)

  • 1. Tapentadol results in less deterioration of gastrointestinal function and symptoms than standard opioid therapy in healthy male volunteers.
    Mark EB; Nedergaard RB; Hansen TM; Nissen TD; Frøkjaer JB; Scott SM; Krogh K; Drewes AM
    Neurogastroenterol Motil; 2021 Nov; 33(11):e14131. PubMed ID: 34051122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system: Effect of opioids.
    Mark EB; Klinge MW; Grønlund D; Poulsen JL; Schlageter V; Scott SM; Krogh K; Drewes AM
    Neurogastroenterol Motil; 2020 Mar; 32(3):e13753. PubMed ID: 31721398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans.
    Jeong ID; Camilleri M; Shin A; Iturrino J; Boldingh A; Busciglio I; Burton D; Ryks M; Rhoten D; Zinsmeister AR
    Aliment Pharmacol Ther; 2012 May; 35(9):1088-96. PubMed ID: 22348605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Although tapentadol and oxycodone both increase colonic volume, tapentadol treatment resulted in softer stools and less constipation: a mechanistic study in healthy volunteers.
    Mark EB; Frøkjær JB; Hansen TM; Nedergaard RB; Drewes AM
    Scand J Pain; 2021 Apr; 21(2):406-414. PubMed ID: 33606931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency.
    Eichenbaum G; Göhler K; Etropolski M; Steigerwald I; Pergolizzi J; Kim M; Vorsanger G
    J Opioid Manag; 2015; 11(3):211-27. PubMed ID: 25985806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
    Etropolski M; Kelly K; Okamoto A; Rauschkolb C
    Adv Ther; 2011 May; 28(5):401-17. PubMed ID: 21494892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of tapentadol and oxycodone on central processing of tonic pain.
    Nedergaard RB; Hansen TM; Nissen TD; Mark EB; Brock C; Drewes AM
    Clin Neurophysiol; 2021 Oct; 132(10):2342-2350. PubMed ID: 34454260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
    Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C
    Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
    Afilalo M; Etropolski MS; Kuperwasser B; Kelly K; Okamoto A; Van Hove I; Steup A; Lange B; Rauschkolb C; Haeussler J
    Clin Drug Investig; 2010; 30(8):489-505. PubMed ID: 20586515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term oxycodone treatment does not affect electrogenic ion transport in isolated mucosa from the human rectosigmoid colon.
    Nilsson M; Brock C; Poulsen JL; Bindslev N; Hansen MB; Louring Christrup L; Drewes AM
    Scand J Gastroenterol; 2016; 51(5):538-47. PubMed ID: 26610166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
    Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
    Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers.
    van der Schrier R; Jonkman K; van Velzen M; Olofsen E; Drewes AM; Dahan A; Niesters M
    Br J Anaesth; 2017 Dec; 119(6):1169-1177. PubMed ID: 29029015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI analysis of fecal volume and dryness: Validation study using an experimental oxycodone-induced constipation model.
    Mark EB; Bødker MB; Grønlund D; Østergaard LR; Frøkjaer JB; Drewes AM
    J Magn Reson Imaging; 2019 Sep; 50(3):733-745. PubMed ID: 30609164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
    Etropolski M; Kuperwasser B; Flügel M; Häufel T; Lange B; Rauschkolb C; Laschewski F
    Adv Ther; 2014 Jun; 31(6):604-20. PubMed ID: 24985410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone.
    Haeseler G; Schaefers D; Prison N; Ahrens J; Liu X; Karch A
    BMC Anesthesiol; 2017 Jul; 17(1):91. PubMed ID: 28693439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.
    Hale M; Upmalis D; Okamoto A; Lange C; Rauschkolb C
    Curr Med Res Opin; 2009 May; 25(5):1095-104. PubMed ID: 19301989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tapentadol and oxycodone reduce cingulate glutamate in healthy volunteers.
    Hansen TM; Frøkjaer JB; Mark EB; Drewes AM
    Br J Clin Pharmacol; 2022 Mar; 88(3):1358-1364. PubMed ID: 34427941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapentadol and oxycodone affect resting-state functional brain connectivity: A randomized, placebo-controlled trial.
    Croosu SS; Frøkjaer JB; Drewes AM; Hansen TM
    J Neuroimaging; 2021 Sep; 31(5):956-961. PubMed ID: 34196442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
    Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid-induced bowel dysfunction in healthy volunteers assessed with questionnaires and MRI.
    Nilsson M; Poulsen JL; Brock C; Sandberg TH; Gram M; Frøkjær JB; Krogh K; Drewes AM
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):514-24. PubMed ID: 26795566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.